Alnylam Pharmaceuticals announced this week that it has completed enrollment in a phase IIb study of its investigational respiratory syncytial virus therapy ALN-RSV01.
The trial is a multi-center, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients, according to the company. It is being conducted at lung-transplant centers in six countries. As previously disclosed, data are expected to be reported mid-2012 (GSN 11/3/2011).